AHMEDABAD: Zydus, part of Ahmedabad-based Cadila Healthcare, on Friday said it received approval from the Drugs Controller General of India to conduct Phase I and II human clinical trials for its Covid-19 vaccine candidate ‘ZyCoV-D’.
This is the second Indian vaccine candidate to get approval for human trials.
Zydus said the potential vaccine showed a “strong immune response” in animal studies.
On June 29, Hyderabad-based Bharat Biotech said its COVID-19 vaccine candidate ‘COVAXIN’ has received approval from the Drugs Controller General of India (DCGI) to conduct Phase I and II human trials.
This made ‘COVAXIN’ India’s first vaccine candidate to receive approval for human trials. The vaccine is developed in collaboration with the ICMR and the National Institute of Virology.